EGFR and cancer: Many patients with adenocarcinoma, a major subtype of lung cancer, harbor mutations in the epidermal growth factor receptor (EGFR) in their cancer tissues and initially show a good response to molecular targeted drugs such as gefitinib, which inhibits the EGFR tyrosine kinase [2, 3].